← Back to patent-cliff list
琥珀酸索利那新/盐酸坦洛新
Tier C — Watch / tradeSolifenacin Succinate/Tamsulosin Hydrochloride
安斯泰来制药集团
Originator
2013
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：ADRA1A、CHRM3
Brand：Vesomni、Volutsa
Indications (approved)：下尿路症状
Regional status
US
无进展
2007-06-01
EU
批准上市
2013-10-07
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Solifenacin Succinate/Tamsulosin Hydrochloride?
Approved indications include: 下尿路症状.
When does the Solifenacin Succinate/Tamsulosin Hydrochloride patent expire?
No public expiry year is available for Solifenacin Succinate/Tamsulosin Hydrochloride yet; this page updates once verified.
How do I get a quote for Solifenacin Succinate/Tamsulosin Hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24